Bruce Greenberg
Interim Chief Financial Officer
Replay available
Aldeyra Therapeutics, Inc. (ALDX) Q3 2022 Earnings Call
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) Q3 2022 earnings conference call, held 2022-11-10. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Dr. Todd Brady
President and Chief Executive Officer
Mark Goodman
SVB Securities
Justin Kim
Oppenheimer
Catherine Novak
Jones Research
Tom Schrader
BTIG
Unnamed Participant
Conference Call Participant
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Aldeyra Therapeutics, Inc..
Replay transcript excerpt
WEBVTT 00:00:00.069 -- 00:00:04.291 ladies and gentlemen thank you for standing by and welcome to the aldera therapeutics 00:00:04.291 -- 00:00:09.694 third quarter 2022 financial results conference call at this time all participants 00:00:09.694 -- 00:00:14.477 are in listen only mode after the speaker's presentations there will be a question and 00:00:14.477 -- 00:00:18.479 answer session i would now like to hand over the conference to the company's interim 00:00:18.479 -- 00:00:23.661 chief financial officer mr bruce greenberg please go ahead sir 00:00:24.122 -- 00:00:25.782 good morning everyone 00:00:25.782 -- 00:00:31.066 With me today is Dr. Todd Brady, our President and Chief Executive Officer. 00:00:31.066 -- 00:00:34.989 This morning, we issued a press release reporting our financial results for the quarter 00:00:34.989 -- 00:00:37.611 ended September 30th, 2022 00:00:37.611 -- 00:00:43.034 and recent corporate highlights. A copy of the press release is available on the investors 00:00:43.034 -- 00:00:47.516 and media section of our website at www.aldera.com. 00:00:50.059 -- 00:00:54.122 Please note that this morning's conference call contains forward-looking statements regarding 00:00:54.122 -- 00:00:57.801 future events in the future performance of Aldera. 00:00:57.801 -- 00:01:02.065 Forward-looking statements include, but are not limited to, statements regarding submission 00:01:02.065 -- 00:01:06.949 of potential new drug applications, potential commercialization, 00:01:06.949 -- 00:01:12.834 the anticipated timing of results from our clinical trials, our projected cash runway, 00:01:12.834 -- 00:01:18.619 our possible or assumed future results of operations, expenses, and financial position, 00:01:18.619 -- 00:01:21.660 and potential growth opportunit...